Developer docs
API playgroundTry for free, no card

Search company profiles

Adjuvance Technologies

Full company profile

uuid0002c6z

Namestring
Adjuvance Technologies
Company typeenum
Private
Founded yearint
2009
Short descriptiontext

Adjuvance Technologies is a privately held biopharmaceutical company founded in 2009 and headquartered in Lincoln, Nebraska, with 11–50 employees. It is led by a CEO, co-founder/CBO, and CSO, and has raised capital from Morningside and the Nebraska Angel Network.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLincoln, United States
HQ citystring
Lincoln
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
vaccine adjuvants, biopharmaceutical products, immunology research, pharmaceutical development, immune response enhancers
Industry2 codes
PRIMARYHLAIAEAI
Vaccine Adjuvants & Formulation Systems
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical adjuvants
Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Adjuvance Technologies is a biopharmaceutical company that develops vaccine adjuvants — specialized compounds designed to enhance the immune response when co-administered with vaccine antigens. The company focuses on proprietary adjuvant chemistry intended for use by vaccine developers and other biopharmaceutical manufacturers. Its commercial scope is research-and-development-driven, supplying enabling technology rather than finished vaccines.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Proprietary vaccine adjuvant technology platform
CategoryBiopharmaceutical adjuvants
Description

A proprietary vaccine adjuvant platform offering specialized immunological-enhancing compounds intended for incorporation into vaccine products. The platform is targeted at vaccine developers and biopharmaceutical manufacturers that need enabling adjuvant technology to improve immune response in their vaccine candidates.

No data
Peers8 records
TypeDirect peer
Description

Dynavax is a direct peer: it commercializes the CpG 1018 adjuvant used in HEPLISAV-B and licensed to vaccine developers globally. Adjuvance Technologies operates in the same vaccine-adjuvant-development niche with a similar independent-platform business model.

TypeBroad incumbent
Description

GSK owns the industry-leading AS01 and AS03 adjuvant systems used in Shingrix and pandemic influenza vaccines. As a broad incumbent it competes with independent adjuvant specialists like Adjuvance for adjuvant licensing partnerships with vaccine developers.

TypeBroad incumbent
Description

Novavax commercializes the Matrix-M saponin-based adjuvant paired with its nanoparticle vaccines. It is comparable as a vaccine developer whose competitive moat depends in part on proprietary adjuvant IP similar in role to what Adjuvance is developing.

TypeBroad incumbent
Description

CSL Seqirus uses the MF59 squalene emulsion adjuvant across its influenza vaccine portfolio. It is comparable as a large vaccine incumbent whose adjuvant platform competes for inclusion in licensed vaccine products.

5Sanofi Pasteur
TypeBroad incumbent
Description

Sanofi Pasteur is a major vaccine developer with internal adjuvant development capabilities. It overlaps with Adjuvance as a potential partner or acquirer for proprietary adjuvant technologies needed in its vaccine pipeline.

TypeBroad incumbent
Description

Merck's vaccine division uses proprietary adjuvant systems in products like Gardasil. Comparable to Adjuvance as a large pharmaceutical incumbent with internal adjuvant IP that competes in the same downstream licensing and partnership markets.

TypeEmerging player
Description

Vaxine is an Australian adjuvant-focused biotech advancing its Advax/squalene-based platform in partnerships. It is comparable to Adjuvance as a small independent adjuvant specialist with a similar R&D-driven, licensing-oriented business model.

TypeEmerging player
Description

BioNTech is an mRNA vaccine developer that incorporates lipid nanoparticle and adjuvant strategies for immune potentiation. It is comparable to Adjuvance as a vaccine developer dependent on effective adjuvants, either developed in-house or licensed, for its product candidates.

Market position
Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Adjuvance Technologies

Biopharmaceutical adjuvantsadjuvancetechnologies.com

Adjuvance Technologies is a privately held biopharmaceutical company founded in 2009 and headquartered in Lincoln, Nebraska, with 11–50 employees. It is led by a CEO, co-founder/CBO, and CSO, and has raised capital from Morningside and the Nebraska Angel Network.

Adjuvance Technologies firmographics

Firmographics
Name
Adjuvance Technologies
Website
https://adjuvancetechnologies.com
Company type
Private
Founded year
2009
Headcount range
11–50 employees
Short description
Adjuvance Technologies is a privately held biopharmaceutical company founded in 2009 and headquartered in Lincoln, Nebraska, with 11–50 employees. It is led by a CEO, co-founder/CBO, and CSO, and has raised capital from Morningside and the Nebraska Angel Network.
Ownership category
akta.pro rank

Adjuvance Technologies industry classification

Industry
Product category
Biopharmaceutical adjuvants
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAEAI
Vaccine Adjuvants & Formulation Systems
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)

Keywords

  • Vaccine adjuvants
  • Biopharmaceutical products
  • Immunology research
  • Pharmaceutical development
  • Immune response enhancers

Where Adjuvance Technologies is headquartered

Location

Headquarters

HQ city
Lincoln
HQ country
United States
HQ region
North America

Markets served

Adjuvance Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Adjuvance Technologies product offering

Product offering

Core offering

Adjuvance Technologies is a biopharmaceutical company that develops vaccine adjuvants — specialized compounds designed to enhance the immune response when co-administered with vaccine antigens. The company focuses on proprietary adjuvant chemistry intended for use by vaccine developers and other biopharmaceutical manufacturers. Its commercial scope is research-and-development-driven, supplying enabling technology rather than finished vaccines.

Differentiator

Problem solved

Functional benefit

Products and services

  • Proprietary vaccine adjuvant technology platform A proprietary vaccine adjuvant platform offering specialized immunological-enhancing compounds intended for incorporation into vaccine products. The platform is targeted at vaccine developers and biopharmaceutical manufacturers that need enabling adjuvant technology to improve immune response in their vaccine candidates.

Companies that use Adjuvance Technologies

Customer profile

Ideal customer profiles2 records

Adjuvance Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Adjuvance Technologies competitors and assessment

Company assessment

Direct peers

  • Dynavax Technologies: Dynavax is a direct peer: it commercializes the CpG 1018 adjuvant used in HEPLISAV-B and licensed to vaccine developers globally. Adjuvance Technologies operates in the same vaccine-adjuvant-development niche with a similar independent-platform business model.

Broad incumbents

  • GSK (Vaccines Business): GSK owns the industry-leading AS01 and AS03 adjuvant systems used in Shingrix and pandemic influenza vaccines. As a broad incumbent it competes with independent adjuvant specialists like Adjuvance for adjuvant licensing partnerships with vaccine developers.
  • Novavax: Novavax commercializes the Matrix-M saponin-based adjuvant paired with its nanoparticle vaccines. It is comparable as a vaccine developer whose competitive moat depends in part on proprietary adjuvant IP similar in role to what Adjuvance is developing.
  • CSL Seqirus: CSL Seqirus uses the MF59 squalene emulsion adjuvant across its influenza vaccine portfolio. It is comparable as a large vaccine incumbent whose adjuvant platform competes for inclusion in licensed vaccine products.
  • Sanofi Pasteur: Sanofi Pasteur is a major vaccine developer with internal adjuvant development capabilities. It overlaps with Adjuvance as a potential partner or acquirer for proprietary adjuvant technologies needed in its vaccine pipeline.
  • Merck & Co. (Vaccines): Merck's vaccine division uses proprietary adjuvant systems in products like Gardasil. Comparable to Adjuvance as a large pharmaceutical incumbent with internal adjuvant IP that competes in the same downstream licensing and partnership markets.

Emerging players

  • Vaxine Pty Ltd: Vaxine is an Australian adjuvant-focused biotech advancing its Advax/squalene-based platform in partnerships. It is comparable to Adjuvance as a small independent adjuvant specialist with a similar R&D-driven, licensing-oriented business model.
  • BioNTech: BioNTech is an mRNA vaccine developer that incorporates lipid nanoparticle and adjuvant strategies for immune potentiation. It is comparable to Adjuvance as a vaccine developer dependent on effective adjuvants, either developed in-house or licensed, for its product candidates.

Market position

Customer concentration

Adjuvance Technologies social profiles

Digital presence

Adjuvance Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Adjuvance Technologies leadership team

Management profile

Number of profiles

Profiles3 records

Adjuvance Technologies funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Adjuvance Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adjuvance Technologies

What does Adjuvance Technologies do?

Adjuvance Technologies is a biopharmaceutical company that develops vaccine adjuvants — specialized compounds designed to enhance the immune response when co-administered with vaccine antigens. The company focuses on proprietary adjuvant chemistry intended for use by vaccine developers and other biopharmaceutical manufacturers. Its commercial scope is research-and-development-driven, supplying enabling technology rather than finished vaccines.

When was Adjuvance Technologies founded?

Adjuvance Technologies was founded in 2009. It employs 11 to 50 people.

Where is Adjuvance Technologies based?

Adjuvance Technologies is headquartered in Lincoln, United States, in the North America region.

Who are Adjuvance Technologies's main competitors?

Dynavax Technologies is listed as a direct peer. Broad incumbents are GSK (Vaccines Business), Novavax, CSL Seqirus, Sanofi Pasteur and Merck & Co. (Vaccines). Emerging players are Vaxine Pty Ltd and BioNTech.

Does Adjuvance Technologies have an API?

No public API is recorded for Adjuvance Technologies.

What industry is Adjuvance Technologies in?

Adjuvance Technologies's product category is Biopharmaceutical adjuvants. Its primary akta.pro industry code is HLAIAEAI, Vaccine Adjuvants & Formulation Systems, with a secondary code of HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection). Its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals